Suggestions
Rich Losier
Managing Partner at Rainmaker Venture Group, L.L.C. & Little Creek Solutions (Intellectual Property Division of RVG)
Rich Losier is a Principal at Little Creek Solutions, which is a division of Rainmaker Venture Group. He is recognized as a high-energy, hands-on leader focused on driving innovation through collaboration. His professional background includes a strong emphasis on leadership and innovation, as indicated by his role at Rainmaker Venture Group LLC.1
In addition to his position at Little Creek Solutions, Rich Losier has a history of engaging with industry peers and contributing to various initiatives, particularly in the cybersecurity domain, as evidenced by his involvement in events like the 2023 National Cyber Summit.1
Highlights
Rainmaker Venture Group presenting Cybersecurity 3.0 "Re-instilling Operational Rigor in the Cyber Domain" 2023 National Cyber Summit, Huntsville Alabama
AI/ML and Deep Learning in Medical Advancements
Earlier today while sitting on our front steps with our two Akitas watching our world (albeit it with a light drizzle) come alive as God opened up yet another beautiful day, I had this thought based on a recent conversation had with a dear friend and fellow safety instructor. As both of us are the beneficiaries of some awesome cancer treatments that result from lots of blood-sweat-tears invested by medical researchers and technologists alike, I was inspired to share a few random thoughts that came to mind, some of which are tangential to an overall white paper being drafted by yours truly.
In short, it'd be a great moment when the dots are connected and we empower and enable the medical community to a greater degree with the outputs of what is being iterated within the realms of research in the fields of AI/ML (Artificial Intelligence/and its subset, Machine Learning) and the its Deep Learning underpinnings.
Just imagine a future where portability (body wear) of real-time (RT) or near real-time(NRT) capabilities including but not limited to dynamic imagery, chemo and radiation oncology dispensation methods will be available for actioning on cancerous tissue and its abatement. Relying on static analysis followed by long time gaps as workers draft and load static prescriptive programs and routines will be a solution of the past.
Processing the reams of unstructured data associated within these ecosystems will be what AI/ML techniques and models will afford as accelerators in pharmacological, surgical, and radiological branches of medicine in the battle against cancer. While my colleague and I are extremely grateful for the God-given miracles that we have to-date via the labors of contemporary researchers, we are excited about what the future may hold for others as techniques evolve and are productized. V/R-- RJL
